In today’s recent session, 7.61 million shares of the AnaptysBio Inc (NASDAQ:ANAB) have been traded, and its beta is 0.03. Most recently the company’s share price was $12.76, and it changed around $0.38 or 3.11% from the last close, which brings the market valuation of the company to $388.26M. ANAB at last check was trading at a discount to its 52-week high of $41.31, offering almost -223.75% off that amount. The share price’s 52-week low was $12.21, which indicates that the recent value has risen by an impressive 4.31% since then. We note from AnaptysBio Inc’s average daily trading volume that its 10-day average is 0.59 million shares, with the 3-month average coming to 672.08K.
AnaptysBio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended ANAB as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. AnaptysBio Inc is expected to report earnings per share of -1.7 for the current quarter.
AnaptysBio Inc (NASDAQ:ANAB) trade information
Instantly ANAB has been showing a green trend so far today with a performance of 3.11% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 16.21 on recent trading dayincreased the stock’s daily price by 21.28%. The company’s shares are currently down -3.63% year-to-date, but still down -20.55% over the last five days. On the other hand, AnaptysBio Inc (NASDAQ:ANAB) is -12.72% down in the 30-day period. We can see from the shorts that 6.03 million shares have been sold at a short interest cover period of 8.97 day(s).
The consensus price target as assigned by Wall Street analysts is $35, which translates to bulls needing to increase their stock price by 63.54% from its current value. Analyst projections state that ANAB is forecast to be at a low of $19 and a high of $90.
AnaptysBio Inc (ANAB) estimates and forecasts
The year-over-year growth rate is expected to be 225.96%, up from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 7.79M in revenue for the current quarter. 9 analysts expect AnaptysBio Inc to make 10.02M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 9.01M and 7.18M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -13.54%. Forecasts for the next quarter put sales growth at 39.61%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -19.45%. AnaptysBio Inc earnings are expected to increase by -0.07% in 2025, but the outlook is positive 4.69% per year for the next five years.
AnaptysBio Inc (NASDAQ:ANAB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.74% of AnaptysBio Inc shares, and 118.56% of them are in the hands of institutional investors. The stock currently has a share float of 120.65%. AnaptysBio Inc stock is held by 219.0 institutions, with ECOR1 CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 27.4931% of the shares, which is about 7.52 million shares worth $188.48 million.
FMR LLC, with 10.4936% or 2.87 million shares worth $71.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Fidelity Small Cap Growth Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 733.95 shares worth $9.75 million, making up 2.41% of all outstanding shares. On the other hand, Fidelity Small Cap Growth Fund held roughly 625.15 shares worth around $8.31 million, which represents about 2.05% of the total shares outstanding.
